Pfizer (PFE - Get Report) has dominated headlines this year with its failed Allergan (AGN - Get Report) merger and its Anacor Pharmaceuticals (ANAC) purchase. Nevertheless, Tom Forester, portfolio manager for the Forester Value Fund (FVALX - Get Report) , said there is more to the drug giant's stock higher than deal-making. 'Pfizer is not all about acquisitions, it has a great pipeline,' said Forester. 'And it has easier comps on the horizon because it has been over a year since a number of its previous blockbuster drugs came off patent.' Last week Pfizer, up 6.3 percent thus far in 2016, announced its plan to spend $5.2 billion on Anacor Pharmaceuticals to build up its inflammation and immunology business. The deal gives Pfizer access to Crisaborole, an anti-inflammatory drug currently under U.S. Food and Drug Administration review for the treatment of mild-to-moderate atopic dermatitis, or eczema. The Forester Value Fund is down 60 basis points thus far in 2016, according to Morningstar. The $98 million fund has returned an average of 2% annually over the past decade, putting it in the 91% percentile in Morningstar's long/short equity category.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Video
JPM, WFC, GS Earnings: The Economy Is Strong, But There's a Caveat
Here's how to read the bank tea leaves.
Newt Gingrich on Why Investors Should Pay Attention to Biotech
Newt Gingrich explains why he's paying close attention to the biotech sector and gene therapy.
Credit Card, Banking, Mortgage: a Look at the History of JPMorgan Chase
JPMorgan Chase is reporting its second-quarter earnings for 2019. Watch the video timeline to learn more about the company.
Delivering the Dough: Slice into the History of Domino's Pizza
Take a bite of Domino's history as investors react to the latest round of earnings from the pizza-maker.